Cargando…
Lopinavir/ritonavir for treatment of non-hospitalized patients with COVID-19: a randomized clinical trial
OBJECTIVES: Effective and widely available therapies are still needed for outpatients with COVID-19. We aimed to evaluate the efficacy and safety of lopinavir/ritonavir (LPV/r) for early treatment of non-hospitalized individuals diagnosed with COVID-19. METHODS: This randomized, placebo (Plb)-contro...
Autores principales: | Kaizer, Alexander M., Shapiro, Nathan I., Wild, Jessica, Brown, Samuel M., Cwik, B. Jessica, Hart, Kimberly W., Jones, Alan E., Pulia, Michael S., Self, Wesley H., Smith, Clay, Smith, Stephanie A., Ng, Patrick C., Thompson, B. Taylor, Rice, Todd W., Lindsell, Christopher J., Ginde, Adit A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792182/ https://www.ncbi.nlm.nih.gov/pubmed/36581186 http://dx.doi.org/10.1016/j.ijid.2022.12.028 |
Ejemplares similares
-
Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trial
por: Kaizer, Alexander M., et al.
Publicado: (2022) -
Lopinavir/ritonavir monotherapy in clinical practice
por: Caso, A, et al.
Publicado: (2010) -
Lopinavir-Ritonavir-Kombination nicht wirksam
por: Diener, Hans-Christoph
Publicado: (2020) -
Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19
por: Mohsenian Naghani, Shaghayegh, et al.
Publicado: (2023) -
Real-world use of nirmatrelvir–ritonavir: who benefits?
por: Molina, Kyle C, et al.
Publicado: (2023)